Yonsei University
Welcome,         Profile    Billing    Logout  
 16 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Jeeyun
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Recruiting
2
38
RoW
Avelumab and Gemcitabine
Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.
Leiomyosarcoma Metastatic
12/21
12/22
NCT04249739: Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

Active, not recruiting
2
93
RoW
Pembrolizumab, Keytruda, MK3475
Samsung Medical Center
Gastric Cancer
02/24
03/25
NCT04632459: Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Recruiting
2
35
RoW
pembrolizumab plus ramucirumab
Samsung Medical Center
Gastric Cancer
12/22
12/22
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
TMB-H, NCT06365840: A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced Solid Tumor

Not yet recruiting
2
30
NA
IMC-001
ImmuneOncia Therapeutics Inc.
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
12/25
12/27
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Withdrawn
2
115
RoW
EP0057, Olaparib tablets
Ellipses Pharma
Gastric Cancer, Small-cell Lung Cancer
08/24
12/24
GEN001-201, NCT05419362: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Active, not recruiting
2
42
RoW
GEN-001, Avelumab, Bavencio
Genome & Company, Merck KGaA, Darmstadt, Germany
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/24
VIKTORY-2, NCT05620628: Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer

Recruiting
2
25
RoW
Durvalumab, Imfinzi, Savolitinib, AZD6094
Jeeyun Lee
Stomach Cancer, Adenocarcinoma
12/25
12/26
NCT06630130: Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Not yet recruiting
2
50
NA
Trastuzumab deruxtecan, Enhertu, Capecitabine, Xeloda, Rilvegostomig, AZD2936
Jeeyun Lee
Stomach Neoplasms
10/28
06/29
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT03789617: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Recruiting
1/2
72
RoW
EBViNT Cell, Eutil autologous blood-derived T lymphocytes
Eutilex
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
09/22
12/24
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
BBI-20201001, NCT04278144 / 2021-006812-10: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Active, not recruiting
1/2
175
Europe, US, RoW
BDC-1001, Nivolumab, Opdivo
Bolt Biotherapeutics, Inc., Bristol-Myers Squibb
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
01/25
01/26
KEYNOTE-G08, NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US, RoW
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), ENHERTU®, pembrolizumab, KEYTRUDA®
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
11/25
04/27
NCT06085755: Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Recruiting
1/2
61
RoW
Trastuzumab deruxtecan, T-DXd, Afatinib, Giotrif
Jeeyun Lee
Stomach Neoplasm
12/25
12/26
SHIELD-1, NCT03993873: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Active, not recruiting
1
95
Europe, US, RoW
elzovantinib (TPX-0022)
Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
01/24
03/26
NCT05566834: Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

Recruiting
1
36
RoW
Minnelide
Minneamrita Therapeutics LLC
Gastric Cancer
06/24
11/24
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
06/26
09/26
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
NCT02646228: Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer

Recruiting
N/A
500
RoW
molecular profiling, patient derived cells
Samsung Medical Center
Metastatic Cancer
06/22
06/23
NCT02593578: Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.

Recruiting
N/A
2000
RoW
Samsung Medical Center
Metastatic Cancer
12/22
12/23
NCT01831609: Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer

Recruiting
N/A
1000
RoW
Samsung Medical Center
Sarcoma
12/23
12/24
Kim, Nam Kyu
OPTIMIZE-APT, NCT05418556: Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Recruiting
4
3944
RoW
aspirin, clopidogrel, prasugrel, ticagrelor
Asan Medical Center
Coronary Artery Disease
08/27
12/28
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05952596: A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

Not yet recruiting
1
42
NA
DTaP-HepB-IPV-Hib vaccine
LG Chem
Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b Infection
10/23
03/24

Download Options